Tostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, Yu J, Chan CN, Bondoc S, Starke CE, Nekorchuk M, Busman-Sahay K, Piedra-Mora C, Wrijil LM, Ducat S, Custers J, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Lin Z, Mahrokhian SH, Nampanya F, Nityanandam R, Pessaint L, Porto M, Ali V, Benetiene D, Tevi K, Andersen H, Lewis MG, Schmidt AG, Lauffenburger DA, Alter G, Estes JD, Schuitemaker H, Zahn R, Barouch DH.,
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters, Nat Med. 2020 Nov;26(11):1694-1700. doi: 10.1038/s41591-020-1070-6. Epub 2020 Sep 3.
Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Bowen RA, Nussenzweig MC, Sheahan TP.,
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo, J Exp Med. 2021 Mar 1;218(3):e20201993. doi: 10.1084/jem.20201993.
Rosenke K, Meade-White K, Letko M, Clancy C, Hansen F, Liu Y, Okumura A, Tang-Huau TL, Li R, Saturday G, Feldmann F, Scott D, Wang Z, Munster V, Jarvis MA, Feldmann H.,
Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection, Emerg Microbes Infect. 2020 Nov 29:1-36. doi: 10.1080/22221751.2020.1858177. Online ahead of print.
Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, Zhang X, Juelich T, Smith JK, Zhang L, Bopp N, Schindewolf C, Vu M, Vanderheiden A, Swetnam D, Plante JA, Aguilar P, Plante KS, Lee B, Weaver SC, Suthar MS, Routh AL, Ren P, Ku Z, An Z, Debbink K, Shi PY, Freiberg AN, Menachery VD.,
Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis, bioRxiv. 2020 Aug 26:2020.08.26.268854. doi: 10.1101/2020.08.26.268854. Preprint.
Walser, M., Rothenberger, S., Hurdiss, D. L., Schlegel, A., Calabro, V., Fontaine, S., ... & Cornelius, A.,
Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates, bioRxiv. 2020. November 20, 2020. doi: https://doi.org/10.1101/2020.08.25.256339
Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, Schäfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS.,
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo, Science. 2020 Nov 12:eabe8499. doi: 10.1126/science.abe8499. Online ahead of print.
Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY.,
Spike mutation D614G alters SARS-CoV-2 fitness, Nature. 2020 Oct 26. doi: 10.1038/s41586-020-2895-3. Online ahead of print.
Ye G, Gallant JP, Massey C, Shi K, Tai W, Zheng J, Odle AE, Vickers MA, Shang J, Wan Y, Drelich A, Kempaiah KR, Tat V, Perlman S, Du L, Tseng CT, Aihara H, LeBeau AM, Li F.,
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2, bioRxiv. 2020 Nov 17:2020.11.17.386532. doi: 10.1101/2020.11.17.386532. Preprint.
Ellison, T. J., Talbott, G. C., & Henderson, D. R.,
VaxiPatchâ˘, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017, Vaccine 38, no. 43 (2020): 6839-6848.
Liu X, Luongo C, Matsuoka Y, Park HS, Santos C, Yang L, Moore IN, Afroz S, Johnson RF, Lafont BAP, Martens C, Best SM, Munster VJ, HollĂ˝ J, Yewdell JW, Le NouĂŤn C, Munir S, Buchholz UJ.,
A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters., Proc Natl Acad Sci U S A. 2021 Dec 14;118(50). pii: e2109744118. doi: 10.1073/pnas.2109744118.
Halfmann P, Nakajima N, Sato Y, Takahashi K, Accola M, Chibo S, Fan S, Neumann G, Rehrauer W, Suzuki T, Kawaoka Y.,
SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters., J Infect Dis. 2021 Dec 7. pii: jiab587. doi: 10.1093/infdis/jiab587. [Epub ahead of print]
Dowall S, Salguero FJ, Wiblin N, Fotheringham S, Hatch G, Parks S, Gowan K, Harris D, Carnell O, Fell R, Watson R, Graham V, Gooch K, Hall Y, Mizen S, Hewson R.,
Development of a Hamster Natural Transmission Model of SARS-CoV-2 Infection., Viruses. 2021 Nov 9;13(11). pii: 2251. doi: 10.3390/v13112251.
Yamaguchi T, Hoshizaki M, Minato T, Nirasawa S, Asaka MN, Niiyama M, Imai M, Uda A, Chan JF, Takahashi S, An J, Saku A, Nukiwa R, Utsumi D, Kiso M, Yasuhara A, Poon VK, Chan CC, Fujino Y, Motoyama S, Nagata S, Penninger JM, et al.,
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury., Nat Commun. 2021 Nov 23;12(1):6791. doi: 10.1038/s41467-021-27097-8.
Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, Ku Z, An Z, Scharton D, Schindewolf C, Widen SG, Menachery VD, Shi PY, Weaver SC.,
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission., Nature. 2021 Nov 24. doi: 10.1038/s41586-021-04245-0. [Epub ahead of print]
Mulka KR, Beck SE, Solis CV, Johanson AL, Queen SE, McCarron ME, Richardson MR, Zhou R, Marinho P, Jedlicka A, Guerrero-Martin S, Shirk EN, Braxton AM, Brockhurst J, Creisher PS, Dhakal S, Brayton CF, Veenhuis RT, Metcalf Pate KA, Karakousis PC, Zahnow CA, Klein SL, et al.,
Progression and Resolution of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters., Am J Pathol. 2021 Nov 10. pii: S0002-9440(21)00472-7. doi: 10.1016/j.ajpath.2021.10.009. [Epub ahead of print]
Bednash JS, Kagan VE, Englert JA, Farkas D, Tyurina YY, Tyurin VA, Samovich SN, Farkas L, Elhance A, Johns F, Lee H, Cheng L, Majumdar A, Jones D, Mejia OR, Ruane-Foster M, Londino JD, Mallampalli RK, Robinson RT.,
Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling., Transl Res. 2021 Nov 2. pii: S1931-5244(21)00263-2. doi: 10.1016/j.trsl.2021.10.007. [Epub ahead of print]
Tostanoski LH, Yu J, Mercado NB, McMahan K, Jacob-Dolan C, Martinot AJ, Piedra-Mora C, Anioke T, Chang A, Giffin VM, Hope DL, Wan H, Bondzie EA, Mahrokhian SH, Wrijil LM, Bauer K, Pessaint L, Porto M, Piegols J, Faudree A, Spence B, Kar S, et al.,
Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern., Sci Transl Med. 2021 Nov 3;13(618):eabj3789. doi: 10.1126/scitranslmed.abj3789. Epub 2021 Nov 3.
Wheatley AK, Pymm P, Esterbauer R, Dietrich MH, Lee WS, Drew D, Kelly HG, Chan LJ, Mordant FL, Black KA, Adair A, Tan HX, Juno JA, Wragg KM, Amarasena T, Lopez E, Selva KJ, Haycroft ER, Cooney JP, Venugopal H, Tan LL, O Neill MT, et al.,
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain., Cell Rep. 2021 Oct 12;37(2):109822. doi: 10.1016/j.celrep.2021.109822. Epub 2021 Sep 25.
Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, MoyniĂŠ L, et al.,
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19., Nat Commun. 2021 Sep 22;12(1):5469. doi: 10.1038/s41467-021-25480-z.
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, et al.,
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern., Sci Transl Med. 2021 Oct 20;13(616):eabj5413. doi: 10.1126/scitranslmed.abj5413. Epub 2021 Oct 20.
Yen HL, Valkenburg S, Sia SF, Choy KT, Peiris JSM, Wong KHM, Crossland N, Douam F, Nicholls JM.,
Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice., Vet Pathol. 2021 Sep 1:3009858211043084. doi: 10.1177/03009858211043084. [Epub ahead of print]
Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS, Henry C, Woods A, Ma L, Stewart-Jones GB, Bock KW, Minai M, Nagata BM, Periasamy S, Shi PY, Graham BS, Moore IN, et al.,
Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection., J Clin Invest. 2021 Oct 15;131(20). pii: e148036. doi: 10.1172/JCI148036.
Ruiz-Bedoya CA, Mota F, Ordonez AA, Foss CA, Singh AK, Praharaj M, Mahmud FJ, Ghayoor A, Flavahan K, De Jesus P, Bahr M, Dhakal S, Zhou R, Solis CV, Mulka KR, Bishai WR, Pekosz A, Mankowski JL, Villano J, Klein SL, Jain SK.,
(124)I-Iodo-DPA-713 Positron Emission Tomography in a Hamster Model of SARS-CoV-2 Infection., Mol Imaging Biol. 2021 Aug 23:1-9. doi: 10.1007/s11307-021-01638-5. Online ahead of print.
Port JR, Yinda CK, Owusu IO, Holbrook M, Fischer R, Bushmaker T, Avanzato VA, Schulz JE, Martens C, van Doremalen N, Clancy CS, Munster VJ.,
SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters., Nat Commun. 2021 Aug 17;12(1):4985. doi: 10.1038/s41467-021-25156-8.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J.,
A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters., J Virol. 2021 Sep 27;95(20):e0059221. doi: 10.1128/JVI.00592-21. Epub 2021 Aug 11.
Chan CEZ, Seah SGK, Chye H, Massey S, Torres M, Lim APC, Wong SKK, Neo JJY, Wong PS, Lim JH, Loh GSL, Wang D, Boyd-Kirkup JD, Guan S, Thakkar D, Teo GH, Purushotorman K, Hutchinson PE, Young BE, Low JG, MacAry PA, Hentze H, et al.,
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody., PLoS One. 2021 Jun 23;16(6):e0253487. doi: 10.1371/journal.pone.0253487. eCollection 2021.
Roh J, Kitchen R, Guseh JS, McNeill J, Aid M, Martinot A, Yu A, Platt C, Rhee J, Weber B, Trager L, Hastings M, Ducat S, Xia P, Castro C, Atlason B, Churchill T, Carli MD, Ellinor P, Barouch D, Ho J, Rosenzweig A.,
Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics., Res Sq. 2021 Jun 8. pii: rs.3.rs-539712. doi: 10.21203/rs.3.rs-539712/v1.
Yinda CK, Port JR, Bushmaker T, Fischer RJ, Schulz JE, Holbrook MG, Shaia C, de Wit E, van Doremalen N, Munster VJ.,
Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant., Emerg Microbes Infect. 2021 Dec;10(1):1284-1292. doi: 10.1080/22221751.2021.1943539.
Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF.,
An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus., Neuro Oncol. 2021 Nov 2;23(11):1911-1921. doi: 10.1093/neuonc/noab128.
Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, et al.,
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets., Immunity. 2021 Jun 8;54(6):1290-1303.e7. doi: 10.1016/j.immuni.2021.05.001. Epub 2021 May 6.
van der Lubbe JEM, Rosendahl Huber SK, Vijayan A, Dekking L, van Huizen E, Vreugdenhil J, Choi Y, Baert MRM, Feddes-de Boer K, Izquierdo Gil A, van Heerden M, Dalebout TJ, Myeni SK, Kikkert M, Snijder EJ, de Waal L, Stittelaar KJ, Tolboom JTBM, Serroyen J, Muchene L, van der Fits L, Rutten L, et al.,
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease., NPJ Vaccines. 2021 Mar 19;6(1):39. doi: 10.1038/s41541-021-00301-y.
Zhang X, Liu Y, Liu J, Bailey AL, Plante KS, Plante JA, Zou J, Xia H, Bopp NE, Aguilar PV, Ren P, Menachery VD, Diamond MS, Weaver SC, Xie X, Shi PY.,
A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence., Cell. 2021 Apr 15;184(8):2229-2238.e13. doi: 10.1016/j.cell.2021.02.044. Epub 2021 Feb 23.
Selvaraj P, Lien CZ, Liu S, Stauft CB, Nunez IA, Hernandez M, Nimako E, Ortega MA, Starost MF, Dennis JU, Wang TT.,
SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters., Life Sci Alliance. 2021 Feb 11;4(4). pii: e202000886. doi: 10.26508/lsa.202000886. Print 2021 Apr.
Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY.,
Spike mutation D614G alters SARS-CoV-2 fitness., Nature. 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. Epub 2020 Oct 26. Erratum in: Nature. 2021 Jul;595(7865):E1.
Ruiz-Bedoya CA, Mota F, Ordonez AA, Foss CA, Singh AK, Praharaj M, Mahmud FJ, Ghayoor A, Flavahan K, De Jesus P, Bahr M, Dhakal S, Zhou R, Solis CV, Mulka KR, Bishai WR, Pekosz A, Mankowski JL, Villano J, Klein SL, Jain SK.,
(124)I-Iodo-DPA-713 Positron Emission Tomography in a Hamster Model of SARS-CoV-2 Infection, null
Bednash JS, Kagan VE, Englert JA, Farkas D, Tyurina YY, Tyurin VA, Samovich SN, Farkas L, Elhance A, Johns F, Lee H, Cheng L, Majumdar A, Jones D, Mejia OR, Ruane-Foster M, Londino JD, Mallampalli RK, Robinson RT.,
Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling, null
Mulka KR, Beck SE, Solis CV, Johanson AL, Queen SE, McCarron ME, Richardson MR, Zhou R, Marinho P, Jedlicka A, Guerrero-Martin S, Shirk EN, Braxton AM, Brockhurst J, Creisher PS, Dhakal S, Brayton CF, Veenhuis RT, Metcalf Pate KA, Karakousis PC, Zahnow CA, Klein SL, Jain SK, Tarwater PM, Pekosz AS, Villano JS, Mankowski JL; Johns Hopkins COVID-19 Hamster Study Group.,
Progression and Resolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Golden Syrian Hamsters, null
Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, Ku Z, An Z, Scharton D, Schindewolf C, Widen SG, Menachery VD, Shi PY, Weaver SC.,
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission, null
Halfmann PJ, Nakajima N, Sato Y, Takahashi K, Accola M, Chiba S, Fan S, Neumann G, Rehrauer W, Suzuki T, Kawaoka Y.,
SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters, null
Gagne M, Corbett KS, Flynn BJ, Foulds KE, Wagner DA, Andrew SF, Todd JM, Honeycutt CC, McCormick L, Nurmukhambetova ST, Davis-Gardner ME, Pessaint L, Bock KW, Nagata BM, Minai M, Werner AP, Moliva JI, Tucker C, Lorang CG, Zhao B, McCarthy E, Cook A, Dodson A, Teng IT, Mudvari P, Roberts-Torres J, Laboune F, Wang L, Goode A, Kar S, Boyoglu-Barnum S, Yang ES, Shi W, Ploquin A, Doria-Rose N, Carfi A, Mascola JR, Boritz EA, Edwards DK, Andersen H, Lewis MG, Suthar MS, Graham BS, Roederer M, Moore IN, Nason MC, Sullivan NJ, Douek DC, Seder RA.,
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung, null
Maruggi G, Mallett CP, Westerbeck JW, Chen T, Lofano G, Friedrich K, Qu L, Sun JT, McAuliffe J, Kanitkar A, Arrildt KT, Wang KF, McBee I, McCoy D, Terry R, Rowles A, Abrahim MA, Ringenberg MA, Gains MJ, Spickler C, Xie X, Zou J, Shi PY, Dutt T, Henao-Tamayo M, Ragan I, Bowen RA, Johnson R, Nuti S, Luisi K, Ulmer JB, Steff AM, Jalah R, Bertholet S, Stokes AH, Yu D.,
A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models, null
Tostanoski LH, Chandrashekar A, Patel S, Yu J, Jacob-Dolan C, Chang A, Powers OC, Sellers D, Gardner S, Barrett J, Sanborn O, Stephenson KE, Ansel JL, Jaegle K, Seaman MS, Porto M, Lok M, Spence B, Cayer K, Nase D, Holman S, Bradette H, Kar S, Andersen H, Lewis MG, Cox F, Tolboom JTBM, de Groot AM, Heerwegh D, Le Gars M, Sadoff J, Wegmann F, Zahn RC, Schuitemaker H, Barouch DH.,
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters, null
Port JR, Yinda CK, Avanzato VA, Schulz JE, Holbrook MG, van Doremalen N, Shaia C, Fischer RJ, Munster VJ.,
Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo, null
Lee JY, Wing PAC, Gala DS, Noerenberg M, Järvelin AI, Titlow J, Zhuang X, Palmalux N, Iselin L, Thompson MK, Parton RM, Prange-Barczynska M, Wainman A, Salguero FJ, Bishop T, Agranoff D, James W, Castello A, McKeating JA, Davis I.,
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences, null
Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, Darling TL, Joshi A, Loeber S, Singh G, Foster SL, Ying B, Case JB, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio JE, Hernandez-Ortiz JP, Henry AR, Ciuoderis K, Florek KR, Patel M, Odle A, Wong LR, Bateman AC, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche AS, Sordillo EM, Chang LA, van Bakel H, Simon V; Consortium Mount Sinai Pathogen Surveillance (PSP) study group; Douek DC, Sullivan NJ, Thackray LB, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby RJ, Seder RA, Suthar MS, García-Sastre A, Schotsaert M, Suzuki T, Boon ACM, Diamond MS, Kawaoka Y.,
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters, null
Konrath KM, Liaw K, Wu Y, Zhu X, Walker SN, Xu Z, Schultheis K, Chokkalingam N, Chawla H, Du J, Tursi NJ, Moore A, Adolf-Bryfogle J, Purwar M, Reuschel EL, Frase D, Sullivan M, Fry B, Maricic I, Andrade VM, Iffland C, Crispin M, Broderick KE, Humeau LMPF, Patel A, Smith TRF, Pallesen J, Weiner DB, Kulp DW.,
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection, null
Chiba S, Kiso M, Nakajima N, Iida S, Maemura T, Kuroda M, Sato Y, Ito M, Okuda M, Yamada S, Iwatsuki-Horimoto K, Watanabe T, Imai M, Armbrust T, Baric RS, Halfmann PJ, Suzuki T, Kawaoka Y.,
Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model, null
Choudhary S, Kanevsky I, Yildiz S, Sellers RS, Swanson KA, Franks T, Rathnasinghe R, Munoz-Moreno R, Jangra S, Gonzalez O, Meade P, Coskran T, Qian J, Lanz TA, Johnson JG, Tierney CA, Smith JD, Tompkins K, Illenberger A, Corts P, Ciolino T, Dormitzer PR, Dick EJ Jr, Shivanna V, Hall-Ursone S, Cole J, Kaushal D, Fontenot JA, Martinez-Romero C, McMahon M, Krammer F, Schotsaert M, García-Sastre A.,
Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models, null
Halfmann PJ, Kuroda M, Armbrust T, Accola M, Valdez R, Kowalski-Dobson T, Rehrauer W, Gordon A, Kawaoka Y.,
Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model, null
Carroll T, Fox D, van Doremalen N, Ball E, Morris MK, Sotomayor-Gonzalez A, Servellita V, Rustagi A, Yinda CK, Fritts L, Port JR, Ma ZM, Holbrook MG, Schulz J, Blish CA, Hanson C, Chiu CY, Munster V, Stanley S, Miller CJ.,
The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters, null
Hawman DW, Meade-White K, Archer J, Leventhal SS, Wilson D, Shaia C, Randall S, Khandhar AP, Krieger K, Hsiang TY, Gale M, Berglund P, Fuller DH, Feldmann H, Erasmus JH.,
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern, null
Kaufmann E, Khan N, Tran KA, Ulndreaj A, Pernet E, Fontes G, Lupien A, Desmeules P, McIntosh F, Abow A, Moorlag SJCFM, Debisarun P, Mossman K, Banerjee A, Karo-Atar D, Sadeghi M, Mubareka S, Vinh DC, King IL, Robbins CS, Behr MA, Netea MG, Joubert P, Divangahi M.,
BCG vaccination provides protection against IAV but not SARS-CoV-2, null
Hansen F, Meade-White K, Clancy C, Rosenke R, Okumura A, Hawman DW, Feldmann F, Kaza B, Jarvis MA, Rosenke K, Feldmann H.,
SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract, null
Jiang L, Driedonks TAP, Jong WSP, Dhakal S, Bart van den Berg van Saparoea H, Sitaras I, Zhou R, Caputo C, Littlefield K, Lowman M, Chen M, Lima G, Gololobova O, Smith B, Mahairaki V, Riley Richardson M, Mulka KR, Lane AP, Klein SL, Pekosz A, Brayton C, Mankowski JL, Luirink J, Villano JS, Witwer KW.,
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants, null
McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, Halfmann P, Kawaoka Y, Piedra-Mora C, Jain N, Ducat S, Kar S, Andersen H, Lewis MG, Martinot AJ, Barouch DH.,
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters, null
Field CJ, Heinly TA, Patel DR, Sim DG, Luley E, Gupta SL, Vanderford TH, Wrammert J, Sutton TC.,
Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters, null
Weishampel ZA, Young J, Fischl M, Fischer RJ, Donkor IO, Riopelle JC, Schulz JE, Port JR, Saturday TA, van Doremalen N, Berry JD, Munster VJ, Yinda CK.,
OraSure InteliSwab(™) Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern-Alpha, Beta, Gamma, Delta, and Omicron, null
Aid M, Vidal SJ, Piedra-Mora C, Ducat S, Chan CN, Bondoc S, Colarusso A, Starke CE, Nekorchuk M, Busman-Sahay K, Estes JD, Martinot AJ, Barouch DH.,
Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques, null
Halfmann PJ, Kuroda M, Maemura T, Chiba S, Armbrust T, Wright R, Balaram A, Florek KR, Bateman AC, Kawaoka Y.,
Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters, null
Chen M, Pekosz A, Villano JS, Shen W, Zhou R, Kulaga H, Li Z, Beck SE, Witwer KW, Mankowski JL, Ramanathan M, Rowan NR, Lane AP.,
Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants, null
Ilinykh PA, Periasamy S, Huang K, Kuzmina NA, Ramanathan P, Meyer MN, Mire CE, Kuzmin IV, Bharaj P, Endsley JR, Chikina M, Sealfon SC, Widen SG, Endsley MA, Bukreyev A.,
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2, null
Piedra-Mora C, Robinson SR, Tostanoski LH, Dayao DAE, Chandrashekar A, Bauer K, Wrijil L, Ducat S, Hayes T, Yu J, Bondzie EA, McMahan K, Sellers D, Giffin V, Hope D, Nampanya F, Mercado NB, Kar S, Andersen H, Tzipori S, Barouch DH, Martinot AJ.,
Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments, null
Roh JD, Kitchen RR, Guseh JS, McNeill JN, Aid M, Martinot AJ, Yu A, Platt C, Rhee J, Weber B, Trager LE, Hastings MH, Ducat S, Xia P, Castro C, Singh A, Atlason B, Churchill TW, Di Carli MF, Ellinor PT, Barouch DH, Ho JE, Rosenzweig A.,
Plasma Proteomics of COVID-19-Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics, null
Findlay-Wilson S, Easterbrook L, Smith S, Pope N, Humphries G, Schuhmann H, Ngabo D, Rayner E, Otter AD, Coleman T, Hicks B, Graham VA, Halkerston R, Apostolakis K, Taylor S, Fotheringham S, Horton A, Tree JA, Wand M, Hewson R, Dowall SD.,
Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins, null
Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, Widen SG, An Z, Weaver SC, Menachery VD, Xie X, Shi PY.,
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant, null
Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y.,
Characterization of the SARS-CoV-2 B.1.621 (Mu) variant, null
Rosenke K, Okumura A, Lewis MC, Feldmann F, Meade-White K, Bohler WF, Griffin A, Rosenke R, Shaia C, Jarvis MA, Feldmann H.,
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model, null
Fell R, Potter JA, Yuille S, Salguero FJ, Watson R, Ngabo D, Gooch K, Hewson R, Howat D, Dowall S.,
Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection, null
Wussow F, Kha M, Faircloth K, Nguyen VH, Iniguez A, Martinez J, Park Y, Nguyen J, Kar S, Andersen H, Lewis MG, Chiuppesi F, Diamond DJ.,
COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants, null
Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N.,
Parsing the role of NSP1 in SARS-CoV-2 infection, null
Johnson BA, Zhou Y, Lokugamage KG, Vu MN, Bopp N, Crocquet-Valdes PA, Kalveram B, Schindewolf C, Liu Y, Scharton D, Plante JA, Xie X, Aguilar P, Weaver SC, Shi PY, Walker DH, Routh AL, Plante KS, Menachery VD.,
Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis, null
Kurup D, Wirblich C, Zabihi Diba L, Lambert R, Watson M, Shaikh N, Ramage H, Solomides C, Schnell MJ.,
A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model, null
Park HS, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, Ahlers LRH, Moore IN, Afroz S, Johnson RF, Lafont BAP, Dorward DW, Fischer ER, Martens C, Samal SK, Munir S, Buchholz UJ, Le Nouën C.,
Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2, null
Nikitin PA, DiMuzio JM, Dowling JP, Patel NB, Bingaman-Steele JL, Heimbach BC, Henriquez N, Nicolescu C, Polley A, Sikorski EL, Howanski RJ, Nath M, Shukla H, Scheaffer SM, Finn JP, Liang LF, Smith T, Storm N, McKay LGA, Johnson RI, Malsick LE, Honko AN, Griffiths A, Diamond MS, Sarma P, Geising DH, Morin MJ, Robinson MK.,
IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2, null
Wang Z, Popowski KD, Zhu D, de Juan Abad BL, Wang X, Liu M, Lutz H, De Naeyer N, DeMarco CT, Denny TN, Dinh PC, Li Z, Cheng K.,
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine, null
Blanas A, Karsjens H, de Ligt A, Huijbers EJM, van Loon K, Denisov SS, Durukan C, Engbersen DJM, Groen J, Hennig S, Hackeng TM, van Beijnum JR, Griffioen AW.,
Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19, null
Piepenbrink MS, Park JG, Deshpande A, Loos A, Ye C, Basu M, Sarkar S, Khalil AM, Chauvin D, Woo J, Lovalenti P, Erdmann NB, Goepfert PA, Truong VL, Bowen RA, Walter MR, Martinez-Sobrido L, Kobie JJ.,
Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody, null
Vu MN, Lokugamage KG, Plante JA, Scharton D, Bailey AO, Sotcheff S, Swetnam DM, Johnson BA, Schindewolf C, Alvarado RE, Crocquet-Valdes PA, Debbink K, Weaver SC, Walker DH, Russell WK, Routh AL, Plante KS, Menachery VD.,
QTQTN motif upstream of the furin-cleavage site plays a key role in SARS-CoV-2 infection and pathogenesis, null
Arora J, Patel DR, Nicol MJ, Field CJ, Restori KH, Wang J, Froelich NE, Katkere B, Terwilliger JA, Weaver V, Luley E, Kelly K, Kirimanjeswara GS, Sutton TC, Cantorna MT.,
Vitamin D and the Ability to Produce 1,25(OH)(2)D Are Critical for Protection from Viral Infection of the Lungs, null
Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, Kalveram B, Bukreyev A, Ren P, Wang T, Menachery VD, Plante KS, Xie X, Weaver SC, Shi PY.,
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions, null
Espeseth AS, Yuan M, Citron M, Reiserova L, Morrow G, Wilson A, Horton M, Rukhman M, Kinek K, Hou F, Li SL, Li F, Choi Y, Heidecker G, Luo B, Wu G, Zhang L, Strable E, DeStefano J, Secore S, Mukhopadhyay TK, Richardson DD, Sayeed E, Welch LS, Bett AJ, Feinberg MB, Gupta SB, Cooper CL, Parks CL.,
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera, null
Hawman DW, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal SS, Rao D, Stamper A, Lewis M, Rosenke R, Krieger K, Randall S, Khandhar AP, Hao L, Hsiang TY, Greninger AL, Gale M Jr, Berglund P, Fuller DH, Rosenke K, Feldmann H, Erasmus JH.,
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine, null
van Doremalen N, Schulz JE, Adney DR, Saturday TA, Fischer RJ, Yinda CK, Thakur N, Newman J, Ulaszewska M, Belij-Rammerstorfer S, Saturday G, Spencer AJ, Bailey D, Russell CA, Gilbert SC, Lambe T, Munster VJ.,
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants, null
Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, Gömer A, Postmus D, Gogesch P, Niles M, Plesker R, Miskey C, Gellhorn Serra M, Breithaupt A, Hörner C, Kruip C, Ehmann R, Ivics Z, Waibler Z, Pfaender S, Wyler E, Landthaler M, Kupke A, Nouailles G, Goffinet C, Brown RJP, Mühlebach MD.,
Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after T(H)2-biased immunization, null
Mudrick HE, Massey S, McGlinch EB, Parrett BJ, Hemsath JR, Barry ME, Rubin JD, Uzendu C, Hansen MJ, Erskine CL, Van Keulen VP, Drelich A, Panos JA, Fida M, Suh GA, Peikert T, Block MS, Tseng CK, Olivier GR, Barry MA.,
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2, null
Assmus F, Driouich JS, Abdelnabi R, Vangeel L, Touret F, Adehin A, Chotsiri P, Cochin M, Foo CS, Jochmans D, Kim S, Luciani L, Moureau G, Park S, Pétit PR, Shum D, Wattanakul T, Weynand B, Fraisse L, Ioset JR, Mowbray CE, Owen A, Hoglund RM, Tarning J, Lamballerie X, Nougairède A, Neyts J, Sjö P, Escudié F, Scandale I, Chatelain E.,
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19, null
Forero C, Ritter JM, Seixas JN, Coleman-McCray JD, Brake M, Condrey JA, Tansey C, Welch SR, Genzer SC, Spengler JR.,
Volume-Associated Clinical and Histopathological Effects of Intranasal Instillation in Syrian Hamsters: Considerations for Infection and Therapeutic Studies, null
Wing PAC, Prange-Barczynska M, Cross A, Crotta S, Orbegozo Rubio C, Cheng X, Harris JM, Zhuang X, Johnson RL, Ryan KA, Hall Y, Carroll MW, Issa F, Balfe P, Wack A, Bishop T, Salguero FJ, McKeating JA.,
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model, null
Hajnik RL, Plante JA, Liang Y, Alameh MG, Tang J, Bonam SR, Zhong C, Adam A, Scharton D, Rafael GH, Liu Y, Hazell NC, Sun J, Soong L, Shi PY, Wang T, Walker DH, Sun J, Weissman D, Weaver SC, Plante KS, Hu H.,
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models, null
Vaivode K, Verhovcova I, Skrastina D, Petrovska R, Kreismane M, Lapse D, Kalnina Z, Salmina K, Rubene D, Pjanova D.,
Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo, null
Parzych EM, Du J, Ali AR, Schultheis K, Frase D, Smith TRF, Cui J, Chokkalingam N, Tursi NJ, Andrade VM, Warner BM, Gary EN, Li Y, Choi J, Eisenhauer J, Maricic I, Kulkarni A, Chu JD, Villafana G, Rosenthal K, Ren K, Francica JR, Wootton SK, Tebas P, Kobasa D, Broderick KE, Boyer JD, Esser MT, Pallesen J, Kulp DW, Patel A, Weiner DB.,
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2, null
Schindewolf C, Lokugamage K, Vu MN, Johnson BA, Scharton D, Plante JA, Kalveram B, Crocquet-Valdes PA, Sotcheff S, Jaworski E, Alvarado RE, Debbink K, Daugherty MD, Weaver SC, Routh AL, Walker DH, Plante KS, Menachery VD.,
SARS-CoV-2 Uses Nonstructural Protein 16 to Evade Restriction by IFIT1 and IFIT3, null
Lam JH, Shivhare D, Chia TW, Chew SL, Sinsinbar G, Aw TY, Wong S, Venkataraman S, Lim FWI, Vandepapeliere P, Nallani M.,
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine, null
Kehrer T, Cupic A, Ye C, Yildiz S, Bouhhadou M, Crossland NA, Barrall E, Cohen P, Tseng A, Çağatay T, Rathnasinghe R, Flores D, Jangra S, Alam F, Mena N, Aslam S, Saqi A, Marin A, Rutkowska M, Ummadi MR, Pisanelli G, Richardson RB, Veit EC, Fabius JM, Soucheray M, Polacco BJ, Evans MJ, Swaney DL, Gonzalez-Reiche AS, Sordillo EM, van Bakel H, Simon V, Zuliani-Alvarez L, Fontoura BMA, Rosenberg BR, Krogan NJ, Martinez-Sobrido L, García-Sastre A, Miorin L.,
Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis, null
Chen Z, Zhang P, Matsuoka Y, Tsybovsky Y, West K, Santos C, Boyd LF, Nguyen H, Pomerenke A, Stephens T, Olia AS, Zhang B, De Giorgi V, Holbrook MR, Gross R, Postnikova E, Garza NL, Johnson RF, Margulies DH, Kwong PD, Alter HJ, Buchholz UJ, Lusso P, Farci P.,
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants, null
Patel DR, Minns AM, Sims DG, Field CJ, Kerr AE, Heinly T, Luley EH, Rossi RM, Bator C, Mostafa IM, Hafenstein SL, Lindner SE, Sutton TC.,
Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model, null
Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J.,
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses, null
Liu S, Stauft CB, Selvaraj P, Chandrasekaran P, D'Agnillo F, Chou CK, Wu WW, Lien CZ, Meseda CA, Pedro CL, Starost MF, Weir JP, Wang TT.,
Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters, null
Halfmann PJ, Frey SJ, Loeffler K, Kuroda M, Maemura T, Armbrust T, Yang JE, Hou YJ, Baric R, Wright ER, Kawaoka Y, Kane RS.,
Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses, null
Wang T, Stauft C, Selvaraj P, D'agnillo F, Meseda C, Sangare K, Pedro C, Liu S, Lien C, Weir J, Starost M.,
Active and Passive Immunization of Syrian Hamsters with An Attenuated SARS-CoV-2 Protects against New Variants of Concern, null
Toomer G, Burns W, Garcia L, Henry G, Biancofiori A, George A, Duffy C, Chu J, Sides M, Muñoz M, Garcia K, Nikolai-Yogerst A, Peng X, Westfall L, Baker R.,
Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice, null